AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06282120
Drug: Irinotecan Hydrochloride Liposome Injection ；Fluorouracil ；Leucovorin；immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended dose and regimen of Irinotecan Hydrochloride Liposome Injection is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 3 weeks.It can be combined or partially combined immunotherapy.
Trial: NCT05838391
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As part of the subjects' treatment, 825 mg/meters squared per day, divided into 2 daily doses, will be taken on days of radiotherapy. Capecitabine or 5-FU will be administered per the physician's discretion.
Trial: NCT01207622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06238388
Drug: HSK21542 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.
Trial: NCT06194565
Drug: 99mTc-ABH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive an intravenous injection of 99mTc-ABH2, and undergo a SPECT/CT scan within specified time.
Trial: NCT05638360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patch contains 13g starch and 10c.c. water.
Trial: NCT04613960
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment
Trial: NCT04810390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution
Trial: NCT05490563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sodium chloride injection, 0.9%, USP)
Trial: NCT04673422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
Trial: NCT04994535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injection
Trial: NCT06560593
Drug: NTQ5082
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ascending dose, randomized, double-blind study，with 8 dose groups preset. The first cohort will be the sentinel group, consisted of 2 subjects receiving NTQ5082 capsules. The remaining cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
Trial: NCT06560593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple ascending dose, randomized, double-blind study，with 3 dose groups preset. All cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
Trial: NCT04150042
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ethanol (to be given in conjunction with the other listed drugs).
Trial: NCT06612840
Drug: GNC-077
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT02630121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proportion of the subjects with 50% reduction in AHI.
Trial: NCT05251727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight based dose of reconstituted treatment
Trial: NCT06790589
Drug: Levothyroxine Oral Tablet [Synthroid]
RxNorm normalized name: levothyroxine Oral Tablet [Synthroid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Round, colour coded, scored tablet debossed with SYNTHROID on one side and potency on the other side.
Trial: NCT06040840
Drug: Lidocaine + Epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WALANT technique with lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine.
Trial: NCT04732845
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60mg/Kg on day -6
Trial: NCT04750954
Drug: Peposertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05639114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo s.c. monthly
Trial: NCT05819502
Drug: Restylane line of injectables
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
Trial: NCT06592833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo.
Trial: NCT06602453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as per pre-defined regimen.
Trial: NCT00124111
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00124111
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06568692
Drug: PCS6422 and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
Trial: NCT06568692
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercially available capecitabine is a commonly used oral fluoropyrimidine.
Trial: NCT05814432
Drug: L-AmB standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
Trial: NCT06374459
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.
Trial: NCT06374459
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard of care. Will receive zoledronic acid or denosumab.
Trial: NCT06506136
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive fluoxetine tablets, 20 mg each, taken orally twice a day (total daily dose of 40 mg) for 12 weeks. Tablets should be taken with water at the same times daily.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~Bisacodyl: 5-10 mg Glycerin Enema: 110 ml Polyethylene Glycol: 10 g Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM.
Trial: NCT06506136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the Placebo Control Group will receive placebo tablets that are identical in appearance and taste to the fluoxetine tablets. They will take one placebo tablet orally twice a day for 12 weeks, following the same schedule as the treatment group to maintain blinding.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~Bisacodyl: 5-10 mg Glycerin Enema: 110 ml Polyethylene Glycol: 10 g Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM.
Trial: NCT06501664
Drug: LV
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV 400 mg/m²
Trial: NCT06144983
Drug: Alvogyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the first study group, (0.2gm) of Alvogyl paste (Septodont Inc., France), was inserted inside the alveolus, filling it entirely
Trial: NCT05174000
Drug: Test Euthyrox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4.
Trial: NCT05174000
Drug: Reference Euthyrox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4.
Trial: NCT00000873
Drug: Infant Formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05826327
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil for labour analgesia in the control group
Trial: NCT06627257
Drug: LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
Trial: NCT06627257
Drug: LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
Trial: NCT05304585
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00002105
Drug: Doxorubicin hydrochloride (liposomal)
RxNorm normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05594095
Drug: AKT inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKT inhibitor
Trial: NCT05172739
Drug: Opioid-Based Anesthesia-Analgesia Strategy
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Midazolam, Anaesthesia induction \& maintenance: Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium, Desflurane, Morphine, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine Surgical ward: Morphine, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol
Trial: NCT05172739
Drug: Opioid-free Anesthesia-Analgesia Strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Pregabalin, Midazolam, Anesthesia induction \& maintenance: Midazolam, Dexmedetomidine, Lidocaine, Propofol, Ketamine, Hyoscine, Cisatracurium or alternatively Rocuronium, Magnesium sulphate, Dexamethasone, Desflurane, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine, Surgical ward: Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam, Pregabalin, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol
Trial: NCT05778097
Drug: Androgen deprivation therapy(ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
Trial: NCT05243251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug
Trial: NCT06287320
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1/anti-PD-L1 immune checkpoint inhibitors
Trial: NCT05099640
Drug: PTC923
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
Trial: NCT05099640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to PTC923
Trial: NCT05315921
Drug: OsrhAAT 10 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Trial: NCT05315921
Drug: OsrhAAT 20 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Trial: NCT05315921
Drug: OsrhAAT 40 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Trial: NCT05315921
Drug: OsrhAAT 60 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Trial: NCT04409873
Drug: Oral-B Mouth Sore mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
Trial: NCT04409873
Drug: CloSYS Ultra Sensitive Rinse mouthwash
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinse and gargle 4 times daily, for 45 seconds, for 4 weeks.
Trial: NCT06025097
Drug: Combination Solution
RxNorm normalized name: Combination solutions for parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
Trial: NCT04409873
Drug: Listerine Zero Mouthwash Product
RxNorm normalized name: Listerine Mouthwash Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.
Trial: NCT06443944
Drug: Cretostimogene Grenadenorepvec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engineered Oncolytic Adenovirus
Trial: NCT04755127
Drug: Intra-articular corticosteroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
Trial: NCT04592315
Drug: Lipovirtide Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dosage of Lipovirtide Injection
Trial: NCT04222023
Drug: Intravenous immunoglobulins (IVIG)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group: administration of a single dose of IVIG at:~* Day 10+/- 4 days~* Day 41 +/- 7 days~* Day 62 +/- 7 days The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day.
Trial: NCT06013150
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.
Trial: NCT06013150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant in Part 1 of the study will receive matching doses of placebo
Trial: NCT04849390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration in the evening at bedtime for 28 days
Trial: NCT05288920
Drug: Transforaminal injection of Steroids alone
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal injection of Steroids alone
Trial: NCT06561607
Drug: TQB2102 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.
Trial: NCT06139029
Drug: 3% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebulization
Trial: NCT06139029
Drug: steroid(beclomethasone dipropionate 400 μg/day) and salbutamol with 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebulization
Trial: NCT05249374
Drug: Recombinant Human Serum Albumin
RxNorm normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/bottle (20%, 50 mL)
Trial: NCT05548465
Drug: Remifentanil Hydrochloride
RxNorm normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive remifentanil anesthesia for operative analgesia.
Trial: NCT05548465
Drug: Sufentanil Citrate
RxNorm normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive sufentanil and remifentanil anesthesia for operative analgesia.
Trial: NCT05289440
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
Trial: NCT05043506
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor monotherapy
Trial: NCT05578443
Drug: 10g Astragalus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus tablets 10g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
Trial: NCT05578443
Drug: 20g Astragalus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus tablets 20g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
Trial: NCT05395052
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lympho-conditioning agent
Trial: NCT06657079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline inhaler
Trial: NCT05226533
Drug: DWRX2003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of DWRX2003
Trial: NCT05226533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of placebo
Trial: NCT06548906
Drug: GZR4 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GZR4 Injection administered sc, once weekly.
Trial: NCT06061575
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fever will be managed with acetaminophen
Trial: NCT06061575
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fever will be managed with ibuprofen
Trial: NCT05089942
Drug: Recombinant Human Insulin Patch ZJSRM2021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）
Trial: NCT05089942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: health subjects receive placebo patch
Trial: NCT05153317
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination granules or tablets for oral administration.
Trial: NCT05048719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05048719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT05411913
Drug: GoodFOR Pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GoodFOR Pain is a FDA registered topical analgesic.
Trial: NCT05411913
Drug: Bengay
RxNorm normalized name: BENGAY Ultra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a FDA OTC registered topical analgesic.
Trial: NCT05411913
Drug: CBD Clinic Muscle and Joint Pain Relief Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a non FDA registered topical analgesic.
Trial: NCT05411913
Drug: CBD FX CBD Muscle and Joint Cream: Cooling Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a non FDA registered topical analgesic.
Trial: NCT05411913
Drug: Essential Wholesale Muscle Gel
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a non FDA registered topical analgesic.
Trial: NCT05411913
Drug: Extract Labs Muscle Cream
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a non FDA registered topical analgesic.
Trial: NCT05020444
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion